Fig. 4

Aberrant key pathways for LUAD. a Mutated genes (BRAF, SETD2 and ARD2 in this case) in the given patient are indicated in thick red border. The background color is determined by the CNAs (gain in read and loss in blue), with the color depth reflecting the frequency of patients who were affected by mutation or CNAs. b A click on a pill icon opens up a window that shows available drugs targeting the gene of interest (BRAF in this example). Drugs are color-coded according to the approval status